SlideShare a Scribd company logo
1 of 12
Monetizing Medical Cannabis
+100 clinical indications:
• Multiple Sclerosis
• Glaucoma
• ALS
• Peripheral Neuropathic Pain
• Post Operative Pain
• Spinal Cord Injury
• Anxiety - PTSD
• Parkinson’s Disease
• Cachexia, Nausea& Vomiting - Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Diseases
Cannabis-based medicine: which molecules
?
Cannabinoids are molecules unique to the
cannabis plant
Initial focus on two principal cannabinoids:
THC (Tetrahydrocannabinol) and CBD
(Cannabidiol)
• THC: Analgesic, Anti-spasmodic,
Anti-tremor,Anti-inflammatory,
Appetite stimulant, Anti-emetic
• CBD: Anti-inflammatory, Anti-
convulsant, Anti-psychotic, Anti-
oxidant, Neuroprotective,
Immunomodulator
Cannabis-based medicine: clinical indications
• Compositions lacking harmful psychotropic components
• Novel cannabis active compounds and derivatives
• Novel cannabis compositions and formulations
• Methods of Production
• Novel drug delivery systems for cannabis
• Novel dosages of cannabis
• Novel medical applications and diseases to treat with cannabis
• Plant breeders rights (PBR) for new cannabis varieties
Cannabis Industry: opportunities are there!
Cannabis Industry: Money is there too!
The market is
estimated to
become $6
billion dollars
industry by 2018.
Cannabis Industry: ready, set, go for the gold rush !
Main companies
Want to join the race?
Think technology
scouting, IP
assesment…
Cannabis Industry: ready, set, go for the gold rush !
Number of granted patents Want to join the race?
Think patent filing
Cannabis Industry: ready, set, go for the gold rush !
Intellectual Property issues are tricky. Cannabis IP rights are uniquely so.
Navigating the cannabis-related IP issues requires extensive knowledge of the
cannabis industry specificity. Getting cannabis IP counseling is a mandatory part
in your drug development program and will guide you through:
• Patent driven competitive analysis
• Patent filing and prosecution
• Patent litigation and enforcement
• Licensing agreements
• Trade Secret Policy documentation and enforcement
• Trade Marks registration and protection
• Plant breeders rights (PBR) registration and enforcement
• Is it safe for patients?
• How does it work?
• Has it been proven to work in preclinical
studies?
• Does the [proposed] mechanism or
pathway through which the drug acts raise
concerns about impact on normal
organs/tissues?
Cannabis-based medicine drug development: ask the expert and
meet the regulator!
• Cannabis is designated as a Schedule I drug (i.e., illegal
with no current medical value)
• Cannabis-based therapeutics requires input from the
U.S. Drug Enforcement Agency (DEA). (not favorable)
• Federally, a drug cannot be prescribed unless it has
undergone clinical trials, yet many states legislation
authorizes the use of medical marijuana without
clinical trials and without identifying specific
indications.
What the regulations
says:
What the regulators
wants to know:
Need to design your preclinical studies to be in compliance with the regulation
Designing the preclinical study: science and regulation
hand in hand
Preclinical studies should be designed as pre-emptive strikes: address
potential future regulatory concerns within the early stage preclinical
development of your molecules, and with the first-in-man study in mind.
Preclinical design considerations:
• GLP vs non-GLP
• Latest regulatory directives
• Pre-IND/IDE meetings: understand what the
regulators wants
• Safety (pharmacology, toxicology)
• Efficacy ( in vivo efficacy)
• Stability (formulation, absorption reproducibility)
• Non-biased design
• Mimic clinical scenario
Designing the preclinical study: science and regulation
hand in hand
Composition? THC/CBD
others…?
Stability?
Mode of Administration?
Dose?
Which models?
What is the “API”?
Unique pharmacology of cannabis-derived
molecules [Bell Shape]- hard to translate
A perfectly tailored preclinical study design goes beyond science.
It adds technological value to your IP rights. How? By understanding the
unique pharmacology of your technology, and matching it with
the most appropriate models, so it translates into clinical indications.
• Match models and technology
• Balance mode of
administration, dose and models
• Translate models into clinical
indications
Science & Regulatory,
Clinical expertise
Creativity” &
Experience
Commitment [
Financial]
Successful drug development: the perfect product arises from
the perfect collaboration
Credit: collaboration by Michael Rojas, executive by Michael Wohlwend, Medical Marijuana by Blaise Sewell, Lawyer by Rflor from the Noun Project from the noun project
IP assets and
protection, Licensing,
Plant Breeders Rights…
Your ideas, your
Molecule[ Financial]
=
Pharmaseed is Israel's largest GLP-
certified pre-clinical CRO specializing
in translational and regenerative
studies. From preclinical to first in
man. We have extensive experiences in
cannabis-based medicine drug
development.
Pharmaseedltd.com
We develop customized, targeted, and
secure comprehensive strategies,
focused on maximizing the benefits of
new technologies and securing wide-
ranging and cost-effective protection
for our clients' inventions, discoveries
and creations. bressler.co.il/ and so-law.co.il/
Successful drug development: the perfect product
arises from the perfect collaboration

More Related Content

Similar to Monetizing Medical Cannabis (2)

Product type- Drug development - Departments of facility- Registration pathwa...
Product type- Drug development - Departments of facility- Registration pathwa...Product type- Drug development - Departments of facility- Registration pathwa...
Product type- Drug development - Departments of facility- Registration pathwa...Asmaa Khalil
 
Drud Discovery - Dr. Amsavel.pdf
Drud Discovery -  Dr. Amsavel.pdfDrud Discovery -  Dr. Amsavel.pdf
Drud Discovery - Dr. Amsavel.pdfDr. Amsavel A
 
Regulatory framework for new drug development
Regulatory framework for new drug developmentRegulatory framework for new drug development
Regulatory framework for new drug developmentDr. Mohit Kulmi
 
Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines Bharathiar university
 
Overview of the Complementary Medicines regulatory framework
Overview of the Complementary Medicines regulatory frameworkOverview of the Complementary Medicines regulatory framework
Overview of the Complementary Medicines regulatory frameworkTGA Australia
 
Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?TGA Australia
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRama Shukla
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agenciesUrmila Aswar
 
Current trends in pharmacy profession
Current trends in pharmacy professionCurrent trends in pharmacy profession
Current trends in pharmacy professionBiswash Sapkota
 
FDA applications in a nutshell
FDA applications in a nutshellFDA applications in a nutshell
FDA applications in a nutshellGwenHb
 
Clinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - PepgraClinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - PepgraPEPGRA Healthcare
 
121725101005-S1.pptx
121725101005-S1.pptx121725101005-S1.pptx
121725101005-S1.pptxTridevSastri1
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdfASSAM DOWN TOWN UNIVERSITY
 
Development mol drug
Development mol drugDevelopment mol drug
Development mol drugswati2084
 

Similar to Monetizing Medical Cannabis (2) (20)

Product type- Drug development - Departments of facility- Registration pathwa...
Product type- Drug development - Departments of facility- Registration pathwa...Product type- Drug development - Departments of facility- Registration pathwa...
Product type- Drug development - Departments of facility- Registration pathwa...
 
PRODUCT AWARENESS LS.pptx
PRODUCT AWARENESS  LS.pptxPRODUCT AWARENESS  LS.pptx
PRODUCT AWARENESS LS.pptx
 
Mead presentation
Mead presentationMead presentation
Mead presentation
 
Drud Discovery - Dr. Amsavel.pdf
Drud Discovery -  Dr. Amsavel.pdfDrud Discovery -  Dr. Amsavel.pdf
Drud Discovery - Dr. Amsavel.pdf
 
Regulatory framework for new drug development
Regulatory framework for new drug developmentRegulatory framework for new drug development
Regulatory framework for new drug development
 
Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines Application for New Drug Discovery (NDD) according to USFDA guidelines
Application for New Drug Discovery (NDD) according to USFDA guidelines
 
Overview of the Complementary Medicines regulatory framework
Overview of the Complementary Medicines regulatory frameworkOverview of the Complementary Medicines regulatory framework
Overview of the Complementary Medicines regulatory framework
 
Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?
 
An overview of the Pharmaceutical Industry
An overview of the Pharmaceutical Industry An overview of the Pharmaceutical Industry
An overview of the Pharmaceutical Industry
 
Emerging Trends prez.ppt
Emerging Trends prez.pptEmerging Trends prez.ppt
Emerging Trends prez.ppt
 
Cannabis Therapy Corp (CTCO) Presentation
Cannabis Therapy Corp (CTCO) PresentationCannabis Therapy Corp (CTCO) Presentation
Cannabis Therapy Corp (CTCO) Presentation
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical Industry
 
Regulatory agencies
Regulatory agenciesRegulatory agencies
Regulatory agencies
 
Current trends in pharmacy profession
Current trends in pharmacy professionCurrent trends in pharmacy profession
Current trends in pharmacy profession
 
FDA applications in a nutshell
FDA applications in a nutshellFDA applications in a nutshell
FDA applications in a nutshell
 
Clinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - PepgraClinical Research Organization Services | Contract Research Company - Pepgra
Clinical Research Organization Services | Contract Research Company - Pepgra
 
121725101005-S1.pptx
121725101005-S1.pptx121725101005-S1.pptx
121725101005-S1.pptx
 
4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf4.2 TT-Approved regulatory bodies and agencies.pdf
4.2 TT-Approved regulatory bodies and agencies.pdf
 
SELLING LAB SERVICES
SELLING LAB SERVICESSELLING LAB SERVICES
SELLING LAB SERVICES
 
Development mol drug
Development mol drugDevelopment mol drug
Development mol drug
 

Monetizing Medical Cannabis (2)

  • 2. +100 clinical indications: • Multiple Sclerosis • Glaucoma • ALS • Peripheral Neuropathic Pain • Post Operative Pain • Spinal Cord Injury • Anxiety - PTSD • Parkinson’s Disease • Cachexia, Nausea& Vomiting - Cancer • Rheumatoid Arthritis • Inflammatory Bowel Diseases Cannabis-based medicine: which molecules ? Cannabinoids are molecules unique to the cannabis plant Initial focus on two principal cannabinoids: THC (Tetrahydrocannabinol) and CBD (Cannabidiol) • THC: Analgesic, Anti-spasmodic, Anti-tremor,Anti-inflammatory, Appetite stimulant, Anti-emetic • CBD: Anti-inflammatory, Anti- convulsant, Anti-psychotic, Anti- oxidant, Neuroprotective, Immunomodulator Cannabis-based medicine: clinical indications
  • 3. • Compositions lacking harmful psychotropic components • Novel cannabis active compounds and derivatives • Novel cannabis compositions and formulations • Methods of Production • Novel drug delivery systems for cannabis • Novel dosages of cannabis • Novel medical applications and diseases to treat with cannabis • Plant breeders rights (PBR) for new cannabis varieties Cannabis Industry: opportunities are there!
  • 4. Cannabis Industry: Money is there too! The market is estimated to become $6 billion dollars industry by 2018.
  • 5. Cannabis Industry: ready, set, go for the gold rush ! Main companies Want to join the race? Think technology scouting, IP assesment…
  • 6. Cannabis Industry: ready, set, go for the gold rush ! Number of granted patents Want to join the race? Think patent filing
  • 7. Cannabis Industry: ready, set, go for the gold rush ! Intellectual Property issues are tricky. Cannabis IP rights are uniquely so. Navigating the cannabis-related IP issues requires extensive knowledge of the cannabis industry specificity. Getting cannabis IP counseling is a mandatory part in your drug development program and will guide you through: • Patent driven competitive analysis • Patent filing and prosecution • Patent litigation and enforcement • Licensing agreements • Trade Secret Policy documentation and enforcement • Trade Marks registration and protection • Plant breeders rights (PBR) registration and enforcement
  • 8. • Is it safe for patients? • How does it work? • Has it been proven to work in preclinical studies? • Does the [proposed] mechanism or pathway through which the drug acts raise concerns about impact on normal organs/tissues? Cannabis-based medicine drug development: ask the expert and meet the regulator! • Cannabis is designated as a Schedule I drug (i.e., illegal with no current medical value) • Cannabis-based therapeutics requires input from the U.S. Drug Enforcement Agency (DEA). (not favorable) • Federally, a drug cannot be prescribed unless it has undergone clinical trials, yet many states legislation authorizes the use of medical marijuana without clinical trials and without identifying specific indications. What the regulations says: What the regulators wants to know: Need to design your preclinical studies to be in compliance with the regulation
  • 9. Designing the preclinical study: science and regulation hand in hand Preclinical studies should be designed as pre-emptive strikes: address potential future regulatory concerns within the early stage preclinical development of your molecules, and with the first-in-man study in mind. Preclinical design considerations: • GLP vs non-GLP • Latest regulatory directives • Pre-IND/IDE meetings: understand what the regulators wants • Safety (pharmacology, toxicology) • Efficacy ( in vivo efficacy) • Stability (formulation, absorption reproducibility) • Non-biased design • Mimic clinical scenario
  • 10. Designing the preclinical study: science and regulation hand in hand Composition? THC/CBD others…? Stability? Mode of Administration? Dose? Which models? What is the “API”? Unique pharmacology of cannabis-derived molecules [Bell Shape]- hard to translate A perfectly tailored preclinical study design goes beyond science. It adds technological value to your IP rights. How? By understanding the unique pharmacology of your technology, and matching it with the most appropriate models, so it translates into clinical indications. • Match models and technology • Balance mode of administration, dose and models • Translate models into clinical indications
  • 11. Science & Regulatory, Clinical expertise Creativity” & Experience Commitment [ Financial] Successful drug development: the perfect product arises from the perfect collaboration Credit: collaboration by Michael Rojas, executive by Michael Wohlwend, Medical Marijuana by Blaise Sewell, Lawyer by Rflor from the Noun Project from the noun project IP assets and protection, Licensing, Plant Breeders Rights… Your ideas, your Molecule[ Financial] =
  • 12. Pharmaseed is Israel's largest GLP- certified pre-clinical CRO specializing in translational and regenerative studies. From preclinical to first in man. We have extensive experiences in cannabis-based medicine drug development. Pharmaseedltd.com We develop customized, targeted, and secure comprehensive strategies, focused on maximizing the benefits of new technologies and securing wide- ranging and cost-effective protection for our clients' inventions, discoveries and creations. bressler.co.il/ and so-law.co.il/ Successful drug development: the perfect product arises from the perfect collaboration

Editor's Notes

  1. Utility: There must be a demonstrated utility, or an assertion of utility believable by one of skill in the art Novelty: What is disclosed must be different from what is already known Non-obviousness: Others have tried and failed Unexpected results, etc.